Glenmark's consolidated revenue rises 7.96% to Rs. 27,674.89 Mn

▴ Glenmark's consolidated revenue rises 7.96% to Rs. 27,674.89 Mn
India Business grew by 14.52 % to Rs. 7,647.53 Mn.

Glenmark Pharmaceuticals Limited, a research-led global integrated pharmaceutical company, today announced its financial results for the fourth quarter and year ended March 31, 2020.

For the Fourth Quarter of FY 2019-20, Glenmark's consolidated revenue was at Rs. 27,674.89 Mn. as against Rs. 25,634.74 Mn. recording an increase of 7.96 %.

Consolidated Net Profit was at Rs. 2203.08 Mn. for the quarter ended March 31, 2019, as compared to Rs. 1,616.62 Mn. in the previous corresponding quarter, registering an increase of 36.28%.

Consolidated EBITDA grew by 27.89% to Rs. 4656.87 Mn. in the quarter ended March 31, 2020, as against Rs. 3,641.31 Mn. in the previous corresponding quarter.

For the year ended March 31, 2020, Glenmark's consolidated revenue was at Rs. 106,409.69 mn as against Rs. 98,654.69 Mn., recording an increase of 7.86% over the previous corresponding period. Consolidated Net Profit was at Rs. 7759.70 Mn. for the year ended March 31, 2020, as against Rs. 9,249.93 Mn. in the previous year. Consolidated EBITDA for the fiscal year ended March 31, 2020, stood at Rs. 16980.82 Mn. as against Rs. 15,857.99 Mn. in the previous corresponding period.

"Our growth momentum sustained in the Fourth Quarter despite the COVID-19 pandemic and challenging generic business environment across markets globally. Our India, Europe and Latin America regions performed well during the Quarter," said Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals Ltd. He further added, "Our sustained performance has been due to the continuous efforts of all our employees around the world. Our manufacturing facilities have operated continuously and facilitated the uninterrupted supply of medicines to operating markets."

Details

1. GLENMARK PHARMACEUTICALS LTD. (GPL)

India

Sales from the formulation business in India for the Fourth Quarter of FY 2019-20 was at Rs. 7,647.53 mn as against Rs. 6677.94 Mn in the previous corresponding quarter, recording growth of 14.52 %.

Glenmark Consumer Care Business

Glenmark Consumer Care business continued to maintain a strong growth momentum of 31 % in the quarter of this financial year and the business setting a new milestone of sales of INR 203.8 crore in this financial year.

USA

Glenmark Pharmaceuticals Inc., USA registered revenue from the sale of finished dosage formulations of Rs. 7,619.02 Mn for the quarter ended March 31, 2020, as against revenue of Rs. 7696 Mn for the previous corresponding quarter, recording a de-growth of (1 %)

Africa, Asia and CIS Region (ROW)

For the Fourth Quarter of FY 2019-20, revenue from Africa, Asia, and the CIS region was Rs. 3365.47 Mn as against Rs. 3852.85 Mn for the previous corresponding quarter, recording de-growth of (12.65 %)

Europe

Glenmark Europe's operations revenue for the Fourth Quarter of FY 2019-20 was at Rs. 4115.68 mn as against Rs. 3184.07 Mn recording a growth of 29.26 %.

Latin America

Glenmark's revenue from its Latin American and Caribbean operations was at Rs. 1768.73 Mn for the Fourth Quarter of FY 2019-20, as against Rs. 1204.07 Mn., recording an increase of 46.9 %.

API Business

For the Fourth Quarter of FY 2019-20, external sales for Glenmark Life Sciences was at Rs. 2613.79 mn as against Rs. 2487.77 Mn., recording growth of 5.07 % over the corresponding period last year.

For the entire year, external sales of Glenmark Life Sciences recorded revenue of INR. 10239.17 Mn as against Rs. 9493.11 Mn. in the previous financial year, recording growth of 7.86 % over the corresponding period last year.

2. ICHNOS Sciences

For updates on the organization and the pipeline, please log on to www.ichnossciences.com. The pipeline update for the fourth quarter is published

Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with a presence across Generics, Specialty, and OTC business with operations in over 50 countries. Glenmark's key therapy focus areas globally are respiratory, dermatology, and oncology. It is ranked among the top 80 Pharma & Biotech companies in the world in terms of revenue (SCRIP 100 Rankings published in the year 2019).

Tags : #Glenmark #Q4FY2019-20Results #EBITDA #Pharmaceuticals #financial #Sales

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026